A phase II study of PD-1 inhibitor pembrolizumab showed the ORR was 18% (7/40) in soft tissue sarcomas, 5% (1/22) in osteosarcomas and 20% (1/5) in chondrosarcomas 80. This evidence concerns the gene PDCD1 and soft tissue sarcoma.